Lydia Visser
PhD
My research in the Pathology department is mainly focused on immunological aspects of B-cell lymphoma. I study interactions of tumor cells with the microenvironment, and signaling pathways in Hodgkin lymphoma and non-Hodgkin lymphomas.
Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC
Published in: British Journal of Haematology
Access to document
10.1111/bjh.14317
Soluble Galectin-1 (sGal-1, also termed LGALS1), soluble CD163 (sCD163) and soluble CD30 (sCD30) have been reported to be elevated in plasma or serum of patients with classical Hodgkin lymphoma (cHL). We aimed to determine the clinical utility of these biomarkers for evaluation of treatment response compared to thymus and activation regulated chemokine (TARC, also termed CCL17). Plasma or serum samples were prospectively collected among 103 newly diagnosed cHL patients before and after treatment. Levels of sGal-1, sCD163, sCD30 and TARC were correlated with disease characteristics and clinical treatment...
Wouter J. Plattel, Zainab N. D. Alsada, Gustaaf W. van Imhoff, Arjan Diepstra, Anke van den Berg, Lydia Visser
Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients
Published in: Insight : the journal of the American Society of Ophthalmic Registered Nurses
Access to document
10.1172/jci.insight.89631
document
BACKGROUND. Cell-free circulating nucleic acids, including 22-nt microRNAs (miRNAs), represent noninvasive biomarkers for treatment response monitoring of cancer patients. While the majority of plasma miRNA is bound to proteins, a smaller, less well-characterized pool is associated with extracellular vesicles (EVs). Here, we addressed whether EV-associated miRNAs reflect metabolic disease in classical Hodgkin lymphoma (cHL) patients. METHODS. With standardized size-exclusion chromatography (SEC), we isolated EV-associated extracellular RNA (exRNA) fractions and protein-bound miRNA from plasma of cHL patients and healthy subjects. We performed a comprehensive small RNA sequencing analysis and...
Monique A J van Eijndhoven, Josée M Zijlstra, Nils J Groenewegen, Esther E E Drees, Stuart van Niele, S Rubina Baglio, Danijela Koppers-Lalic, Hans van der Voorn, Sten F W M Libregts, Marca H M Wauben, Renee X de Menezes, Jan R T van Weering, Rienk Nieuwland, Lydia Visser, Anke van den Berg, Daphne de Jong, D Michiel Pegtel
Studying the role of oncogenic mir-24-3p in hodgkin lymphom
Y. Yuan, J. Kluiver, J. Koerts, D. de Jong, Bea Rutgers, A. Diepstra, Lydia Visser, Anke Berg, van den
Mutations in CD58 and MYB in Hodgkin Lymphoma
F.R. Abdul Razak, A. Diepstra, D. Jong, J. Koerts, B. Rutgers, J. Kluiver, Lydia Visser, Anke Berg, van den
Mid-treatment TARC and mid-treatment FGD-PET predict for progression free survival in classical hodgkin lymphom